Everything below concerns gastric juice protein. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-22. Numbers and descriptions here follow the published literature rather than marketing material.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
| Property | Value | Notes |
|---|---|---|
| Origin | Fragment of a protein found in human gastric juice | Sequence corresponds to a fifteen-residue portion of the parent protein |
| Sequence | GEPPPGKPADDAGLV | Single linear chain, fifteen amino acids |
| Reported molecular weight | About 1419 daltons | Value quoted consistently in supplier and review literature |
| Regulatory status | Not an approved human medicine in the US or EU | Handled and sold as a research chemical |
| Sports status | Listed as prohibited | Falls under non-approved-substance categories in anti-doping codes |
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
=== Antibody maturation in vitro === The invention of antibody phage display revolutionised antibody drug discovery. Initial work was done by laboratories at the MRC Laboratory of Molecular Biology (Greg Winter and John McCafferty), the Scripps Research Institute (Richard Lerner and Carlos F. Barbas) and the German Cancer Research Centre (Frank Breitling and Stefan Dübel). In 1991, The Scripps group reported the first display and selection of human antibodies on phage. This initial study described the rapid isolation of human antibody Fab that bound tetanus toxin and the method was then extended to rapidly clone human anti-HIV-1 antibodies for vaccine design and therapy. Phage display of antibody libraries has become a powerful method for both studying the immune response as well as a method to rapidly select and evolve human antibodies for therapy. Antibody phage display was later used by Carlos F. Barbas at The Scripps Research Institute to create synthetic human antibody libraries, a principle first patented in 1990 by Breitling and coworkers (Patent CA 2035384), thereby allowing human antibodies to be created in vitro from synthetic diversity elements. Antibody libraries displaying millions of different antibodies on phage are often used in the pharmaceutical industry to isolate highly specific therapeutic antibody leads, for development into antibody drugs primarily as anti-cancer or anti-inflammatory therapeutics. One of the most successful was adalimumab, discovered by Cambridge Antibody Technology as D2E7 and developed and marketed by Abbott Laboratories.
Cardiac troponin C (cTnC) TNNC1 is expressed in cardiac and slow skeletal muscle, while skeletal troponin C (sTnC) TNNC2 is expressed in fast skeletal muscle. sTnC has four calcium ion-binding sites, whereas in cTnC there are only three. The actual amount of calcium that binds to troponin has not been definitively established. Because slow skeletal muscle and myocardium share a type, TnC is not used in diagnostics. Mammals have three troponin I (TnI) genes: the cardiac (TNNI3, cTnI), the slow skeletal (TNNI1), and the fast skeletal (TNNI2). Because the heart uses its own version, blood levels of cTnI is used as a clinical marker. Mammals have three troponin T (TnT) genes: the cardiac (TNNT2, cTnT), the slow skeletal (TNNT1), and the fast skeletal (TNNT3). Again, because the heart uses its own version, cTnT is used as a clinical marker. In addition to the myocardium, there are reports of CTnI and CTnT expression in the wall muscle coat of the vena cava and pulmonary veins, so they do not purely originate from the heart. The expression of cTnT in skeletal tissue of patients with chronic skeletal muscle injuries has been described.
In the 1826 General Convention of Friendship, Commerce and Navigation with the king of Denmark, the United States recognised Greenland as a northern possession of the king, and accepted the trade restrictions that Denmark imposed there. In the Treaty of the Danish West Indies, signed in 1916, the US government explicitly recognised Danish sovereignty over all of Greenland. In the 1941 US–Danish agreement, the American Government "reiterate[d] its recognition of and respect for the sovereignty of the Kingdom of Denmark over Greenland". During World War II, the United States defended Greenland at the request of Danish and Greenlandic officials acting without approval from the central government of Denmark, while it was under Nazi occupation. In the 1951 Greenland Defense Agreement, the United States again recognised the sovereignty of the Kingdom of Denmark over all of Greenland. In the 2004 amendment to the Greenland Defense Agreement, the United States recognised Greenland as "an equal part of the Kingdom of Denmark under the Constitution [with] a wide ranging Greenland Home Rule".
== Diagnosis == The diagnosis of hypomobility relies on evaluating the patient's history, a physical examination, and quantitative measurement of joint range of motion (ROM) in the affected areas. At this time, there is no universally accepted hypomobility syndrome classification system, and the condition is not formally recognized as a unique diagnostic item in the medical literature. Instead, clinicians describe and document hypomobility based on the degree of motion loss, the number of joints involved, and the underlying causes (when known). During a medical history evaluation, providers record the onset and duration of symptoms. Included in this is any events such as trauma, immobilization, or surgery, and the specific activities affected by stiffness. Patients are usually asked to compare how their motion has changed over time, and to identify and characterize their movements that are now restricted or painful. The physical examination includes comparison of active and passive ROM in the affected joints, using the contralateral limb and age (or sex-matched normative values) as reference points for measurements. According to the American Academy of Orthopaedic Surgeons (AAOS) Clinical Measurement Guidelines, restricted ROM is identified when movement is substantially below normative values. In addition to this, end-feel of motion (firm, capsular, or bony) and the presence of pain at the end of ROM are important diagnostic clues.
=== Minimum wages === In May 2026, the Karnataka government revised minimum wages by approximately 60 percent across 81 scheduled sectors. Under the revised structure, the minimum monthly wage for unskilled workers in the Greater Bengaluru area was reported at ₹23,376, while highly skilled workers were entitled to ₹31,114. Rates elsewhere in Karnataka ranged between ₹19,300 and ₹21,251 depending on location and category. Lad described the revision as a long-standing demand of the labour community and said the revised framework was intended to provide greater economic security to workers in the unorganized and specified sectors.
Sources: en.wikipedia.org
== Values for common substances == There are multiple techniques to determine the pKa of a chemical, leading to some discrepancies between different sources. Well measured values are typically within 0.1 units of each other. Data presented here were taken at 25 °C in water. More values can be found in the Thermodynamics section, above. A table of pKa of carbon acids, measured in DMSO, can be found on the page on carbanions.
Juvenile idiopathic arthritis (JIA), also known as juvenile arthritis and formerly known as juvenile rheumatoid arthritis (JRA), is the most common chronic rheumatic disease of childhood, affecting approximately 3.8 to 400 out of 100,000 children. Juvenile refers to disease onset before 16 years of age, while idiopathic refers to a condition with no defined cause, and arthritis is inflammation within the joint. JIA is an autoimmune, noninfective, inflammatory joint disease, the cause of which remains poorly understood. It is characterised by chronic joint inflammation. JIA is a subset of childhood arthritis, but unlike other, more transient forms of childhood arthritis, JIA is a lifelong condition with relapse of disease after treatment discontinuation being common. JIA has clinical and pathologic correlates to adult inflammatory and auto-immune arthritis, with the diseases believed to exist on a continuum from childhood to adulthood. There are six biologically and clinically distinct forms of JIA: oligoarticular JIA, rheumatoid factor negative polyarticular JIA, rheumatoid factor positive polyarticular JIA, enthesitis-related arthritis, psoriatic JIA and systemic JIA. A definitive diagnostic test for JIA is lacking: diagnosis is made clinically by a combination of laboratory and clinical factors. Cancer and other auto-immune or inflammatory conditions are usually considered. The prognosis for children with JIA has improved dramatically over recent decades, particularly with the introduction of biological therapies and a shift towards more aggressive treatment strategies.
== Industrial production == Four large pharmaceutical companies, Monsanto, American Cyanamid, Eli Lilly, and Upjohn, developed commercial rBST products and submitted them to the US Food and Drug Administration (FDA) for approval. Monsanto was the first firm to receive approval; it has been sold in the USA since February 3, 1994. Other countries (Mexico, Brazil, India, Russia, and at least ten others) also approved rBST for commercial use. Monsanto licensed Genentech's patent and marketed their product as "Posilac". In October 2008, Monsanto sold this business, in full, to Eli Lilly and Company for $300 million plus additional consideration.
The account, which repeatedly used racial slurs and claimed that the adult animated series South Park and Family Guy would appear on Disney Junior, was suspended after Disney found the account. The removal of blue checkmarks has had a political impact. Taking advantage of the removal of the blue checkmarks for the Twitter accounts for Chicago mayor Lori Lightfoot, the Chicago Department of Transportation, and the Illinois Department of Transportation, false accounts began appearing claiming that the major expressway Lake Shore Drive would close next month for private traffic. Similarly, an impostor account appeared after the New York City Government account tweeted that it was official. New York representative Alexandria Ocasio-Cortez warned of potential harm in misinformation after the encounter. At least eleven accounts claiming to be the Los Angeles Police Department appeared in the wake of the removal of blue checkmarks. An account claiming to be New York City mayor Eric Adams promised to create a Department of Traffic and Parking Enforcement while slashing funding for the New York City Police Department; the operator of the account was later discovered to be Josh Boerman, co-host of the podcast The Worst of All Possible Worlds, who claimed to have made the account in jest. Election offices for four of the most populous counties in the United States—Cook County, Illinois, Harris County, Texas, Maricopa County, Arizona, and San Diego County, California—were unverified.
=== Places of worship === There are three Church of England churches in Wilmslow: St Bartholomew's, St Anne's and St John's. St Bartholomew's is a 16th-century building, which was modified in the 19th century; it has a turreted bell tower. The first rector of the church was a Thomas Dale, who is buried beneath a headstone presumably engraved by him outside the entrance to the church. Wilmslow Methodist Church occupies a modern building close to the town centre, replacing an 1886 building which itself replaced the original 1798 church, built seven years after John Wesley's death. The Sacred Heart & St Teresa's Church is the Roman Catholic church and dates from the late 19th century. Dean Row Chapel, 2 miles (3.2 km) east of the town centre, is a Grade II* listed building built around the end of the 17th century. Initially Presbyterian, it is now a Unitarian chapel. There is also a United Reformed Church in Wilmslow, close to the town centre.
Sources: en.wikipedia.org
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.
The peptide was named after a protein fraction found in human gastric juice, and the shorter form was called body protection compound. That phrase was shortened to the abbreviation BPC. The number 157 refers to a laboratory designation used in the original isolation work.
Its sequence corresponds to a segment of a protein present in gastric secretions, but the material supplied for research is made synthetically. No commercial product is purified from human or animal tissue. The synthetic route is used because it gives a defined chain length and a reproducible sequence.
Low temperature slows the chemical reactions, such as oxidation and hydrolysis, that break down a peptide chain. Water and oxygen are the main drivers of degradation, so a cold and dry environment extends usable life. Actual shelf life depends on the batch, the salt form, and the container.